Nektar maintained by Merrill Lynch at buy

Nektar Therapeutics was maintained by Merrill Lynch analyst Hari Sambasivam at a buy rating with a price target of $28 per share on news that an FDA advisory panel is slated to discuss its New Drug Application for Exubera in patients with diabetes mellitus on Sept. 8. Nektar shares Friday climbed $0.16, or 0.83%, to $19.40 on volume of 1,084,581 shares versus the three-month running average of 974,703 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.